Arrhythmias manifest frequently in individuals with heart failure, posing a notable threat of mortality and morbidity. While the prevention of sudden cardiac death through ICD therapy remains pivotal, accurate risk stratification remains a challenging task even in 2024. Recent data underscore the early consideration of catheter ablation for ventricular tachycardias. Although antiarrhythmic drug therapy serves as an ancillary measure for symptomatic patients, it does not confer prognostic advantages. The holistic management of arrhythmias in heart failure necessitates a systematic, multidimensional approach that initiates with evidence-based medical therapy for heart failure and integrates device-based and interventional therapies. Noteworthy clinical studies have illustrated the positive prognostic impact of early rhythm control strategies, particularly catheter ablation, in individuals managing heart failure and atrial fibrillation.
Keyphrases
- catheter ablation
- atrial fibrillation
- heart failure
- left atrial
- left atrial appendage
- oral anticoagulants
- direct oral anticoagulants
- left ventricular
- end stage renal disease
- healthcare
- cardiac resynchronization therapy
- percutaneous coronary intervention
- chronic kidney disease
- acute heart failure
- ejection fraction
- type diabetes
- cardiovascular events
- machine learning
- newly diagnosed
- venous thromboembolism
- high resolution
- emergency department
- prognostic factors
- mitral valve
- electronic health record
- heart rate
- coronary artery disease
- cardiovascular disease
- mesenchymal stem cells